On the empirical choice of the time window for restricted mean survival time

Cancer immunotherapy trial design with cure rate and delayed treatment effect

(2019) Jing Wei et al.   STATISTICS IN MEDICINE

Weighted log-rank test for time-to-event data in immunotherapy trials with random delayed treatment effect and cure rate

(2018) Shufang Liu et al.   PHARMACEUTICAL STATISTICS

Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point

(2017) Bo Huang et al.   PHARMACEUTICAL STATISTICS

Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio

(2017) Kyongsun Pak et al.   JAMA Oncology

Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials

(2016) Ludovic Trinquart et al.   JOURNAL OF CLINICAL ONCOLOGY

Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies

(2015) Hajime Uno et al.   ANNALS OF INTERNAL MEDICINE

On the restricted mean survival time curve in survival analysis

(2015) Lihui Zhao et al.   BIOMETRICS

Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis

(2014) Hajime Uno et al.   JOURNAL OF CLINICAL ONCOLOGY

Predicting the restricted mean event time with the subject's baseline covariates in survival analysis

(2013) L. Tian et al.   BIOSTATISTICS

Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study

(2012) Lihui Zhao et al.   Clinical Trials

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

(2009) S Vincent Rajkumar et al.   LANCET ONCOLOGY